New Synthetic Opioid Cychlorphine Sparks Health Concerns

A newly identified synthetic opioid, cychlorphine, has emerged as a concerning drug due to its potency, surpassing that of fentanyl. Health officials have linked it to numerous deaths across the U.S. Tennessee saw a significant number, with reports from the state’s health department noting over 30 fatalities since October 2025. The White House Office of National Drug Control Policy highlighted at least 41 deaths in Tennessee between July 2025 and February 2026, alongside at least 55 nationwide.

Fatalities have also been reported in Illinois, California, and Oklahoma. Known for its strength, even minimal quantities of cychlorphine can induce respiratory arrest, noted the Los Angeles County Department of Public Health.

Dr. Nicholas Kardaras, CEO of the New York Center for Living and a clinical professor at Stony Brook Medicine, described cychlorphine as comparable to an intensified version of fentanyl. The Drug Enforcement Administration has identified cychlorphine as a novel synthetic opioid that interacts with the same receptors as fentanyl, without being regulated. It causes severe sedation, respiratory depression, and potentially fatal outcomes.

Cychlorphine is present in illicit substances and counterfeit pills. Its usage might be particularly prevalent among youth, who experiment with drugs or unknowingly acquire it in counterfeit forms, Kardaras pointed out.

Kardaras described cychlorphine as one of the most potent synthetic opioids available and noted its potency as up to 10 times that of fentanyl, making it 500 times more potent than morphine or heroin. “This drug makes fentanyl appear less concerning,” he explained.

People might consume cychlorphine inadvertently as it is often mixed with other drugs or sold in counterfeit pills,” Kardaras warned.

Cychlorphine is available in varied forms, such as pills, powder for snorting, or prepared for intravenous use. Although some users seek cychlorphine for its potency, others might unwittingly consume it. The allure of powerful substances remains a concern, as some individuals pursue them due to their reported strength.

This synthetic drug, while largely accessed through street deals or online platforms, poses significant overdose risks. Kardaras highlighted the vulnerability of younger demographics, who are more inclined to experiment with drugs or purchase dubious pills.

Naloxone, marketed as Narcan, can mitigate the opioid effects of cychlorphine, though multiple doses may be necessary for reversal, according to anecdotal evidence. Kardaras observed that what traditionally needed one or two Narcan doses could now demand five or six for cychlorphine overdoses.

Another concern is the detection challenges, as cychlorphine evades standard fentanyl test strips and hospital urine screenings. “Current drug tests are crafted for specific chemical structures, and cychlorphine is not yet included,” Kardaras explained.

The DEA stresses the immediate use of naloxone, calling 911, and readiness for additional doses. The agency and experts like Kardaras emphasize the continuous struggle against evolving synthetic drugs.